文献速递胸部肿瘤放疗

立体定向体部放疗对早期非小细胞肺癌患者总生存期的影响

The impact of stereotactic body radiation therapy on the overall survival of patients diagnosed with early-stage non-small cell lung cancer.
PubMed 文献 · Radiother Oncol · 2020-10-24

本研究基于美国国家癌症数据库,比较了接受立体定向体部放疗(SBRT)与仅观察的cT1-3 cN0 cM0非小细胞肺癌(NSCLC)患者的总生存期(OS)。多因素分析显示SBRT与OS改善相关(HR 0.56,p<0.001),且获益程度在高龄、更高T分期、更高合并症评分及更近诊断年代的患者中更明显。

要点

  • SBRT与早期NSCLC患者OS改善相关,多因素HR为0.56(p<0.001)。
  • SBRT对OS的获益随T分期升高、年龄增大、合并症评分增加而增大。
  • 诊断年代越近,SBRT对OS的获益幅度越大(HR从2004年0.65降至2015年0.51)。

核心结论

  • 在早期NSCLC患者中,SBRT与观察相比与总生存期改善相关。
  • SBRT对OS的影响幅度在高龄、更高T分期、更高合并症评分及更近治疗年代的患者中增加。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性队列研究,纳入cT1-3 cN0 cM0 NSCLC患者。
  • 共纳入50,819例患者,其中27,027例(53.18%)接受SBRT,23,792例(46.82%)仅观察。
  • 采用多因素Cox比例风险模型校正年龄、种族、性别、收入、教育、居住地、医院类型、保险状态、合并症评分、组织学类型及诊断年份。

主要发现

  • 多因素Cox分析显示SBRT与观察相比OS改善(HR 0.56,p<0.001)。
  • 按T分期分层,SBRT vs 观察的HR从cT1的0.73降至cT3的0.68。
  • 按诊断年份分层,HR从2004年的0.65降至2015年的0.51。
  • 按年龄分层,HR从<50岁的1.04降至≥80岁的0.58。
  • 按Charlson合并症评分分层,HR从评分0的0.69降至评分2的0.58。

临床怎么用

  • 对于不可手术的早期NSCLC患者,SBRT是可考虑的治疗选择,与观察相比可改善总生存期。
  • 在高龄、更高T分期、更高合并症评分及更近诊断年代的患者中,SBRT对OS的获益可能更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Stereotactic Body Radiotherapy (SBRT) has emerged as a standard treatment for inoperable early-stage non-small cell lung cancer (NSCLC) with remarkable local control. However, it is not clear if this local control translates to overall survival (OS). The objective of this study is to investigate the impact of SBRT on the OS of early-stage NSCLC patients and examine if the extent of this impact changes with the era of diagnosis, T stage, age, and comorbidity status. MATERIALS AND METHODS: Using the National Cancer Database, we compared the OS of cT1-3 cN0 cM0 NSCLC patients with SBRT or observation. Multivariable analyses were adjusted for age, race, sex, income, education, place of living, hospital type, insurance status, comorbidity score, histology types, and diagnosis year. RESULTS: Among 50,819 patients, 27,027 (53.18%) received SBRT and 23,792 (46.82%) were observed. Multivariable Cox Proportional-Hazards analysis demonstrated SBRT was associated with an improved OS compared to observation (HR:0.56, p < 0.001). Subset multivariable Cox Proportional-Hazards analyses stratified by T stage, year of diagnosis, age, or Charlson Score revealed that HRs of SBRT vs. observation decrease from cT1 to cT3 (0.73-0.68), from 2004 to 2015 (0.65-0.51), from <50 to ≥80 years old (1.04-0.58) and from a Charlson Score 0 to 2 (0.69-0.58). CONCLUSION: SBRT was associated with improved OS compared to no treatment in early-stage NSCLC. The magnitude of the impact of SBRT on OS increases in patients with advanced age, higher T stages, higher comorbidity scores and more recent treatment eras.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Amin SA, Alam M, Baine MJ, et al. The impact of stereotactic body radiation therapy on the overall survival of patients diagnosed with early-stage non-small cell lung cancer. Radiother Oncol. 2020. PMID: 33317997. doi:10.1016/j.radonc.2020.10.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。